IGF1 and neoplasm: These limitations underscore the potential advantage of targeting the upstream GH–GHR axis, which can simultaneously reduce circulating IGF1 levels, suppress IGF1R signaling in the TME, and attenuate tumor-promoting pathways [10,21,56].